Travere Therapeutics Inc Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
Analyst Coverage
14analysts covering
FY Revenue (est.)
$721.5Mnext fiscal year
FY EPS (est.)
$1.76next fiscal year
Monitoring Framework
Key Performance Indicators
FILSPARI U.S. Net Product Sales Quarterly105.2MTarget: Estimated >$3B potential peak sales opportunity in the U.S.
New Patient Start Forms (PSFs) for FILSPARI in IgAN Quarterly993.0Target: Continued growth driven by new and repeat prescribers
Total U.S. Net Product Sales Quarterly124.5MTarget: Sustainable revenue growth and value creation
Watch Items
- Phase 3 HARMONY Study of pegtibatinase in classical HCUTrigger: First new patient dosed in restarted study (April 2026)Action: Monitor clinical trial progress, patient enrollment rates, and upcoming data readouts
- SPARX Study evaluating FILSPARI in post-transplant patients with recurrent IgAN or FSGSTrigger: On track to complete enrollment in Q2 2026Action: Verify completion of enrollment and track timeline for primary endpoint analysis
- Commercial launch of FILSPARI in FSGSTrigger: FDA approval granted in April 2026Action: Track initial physician adoption, payer coverage, and early sales contributions starting in Q2 2026
Research as of 19 Jun 2026